Acknowledgement
This research was supported by the "Korea National Institute of Health" research project No. 2021-NI-014-01 and 2022-NI-013-01.
References
- Cowman S, van Ingen J, Griffith DE, Loebinger MR. 2019. Nontuberculous mycobacterial pulmonary disease. Eur. Respir. J. 54: 1900250.
- Koh W-J. 2017. Nontuberculous mycobacteria-overview. Microbiol. Spectr. 5: 10.1128/microbiolspec. tnmi1127-0024-2016.
- Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace Jr RJ, Andrejak C, et al. 2020. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin. Infect. Dis. 71: e1-e36.
- Kim J-Y, Kwak N, Yim J-J. 2022. The rise in prevalence and related costs of nontuberculous mycobacterial diseases in South Korea, 2010-2021. Open Forum Infecti. Dis. 9: ofac649.
- Yoon HJ, Choi HY, Ki M. 2017. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea. BMC Infect. Dis. 17: 432.
- Gupta RS, Lo B, Son J. 2018. Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera. Front. Microbiol. 9: 67.
- Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Hall GS, Lin G, et al. 2019. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Mar. Report No.: M24-A2. CLSI Standards: Guidelines for Health Care Excellence.
- Guillemin I, Jarlier V, Cambau E. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42: 2084-2088.